Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 4/20 | 0.56 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 10/20 | 0.49 |
| ▸ | AXL | P30530 | 2/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174159 | 0.94 | PDGFRA (0.59) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL29487188 | 0.94 | PDGFRA (0.59) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL30697769 | 0.92 | PDGFRA (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL165288 | 0.92 | PDGFRA (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL13936618 | 0.92 | PDGFRA (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL20032555 | 0.87 | PDGFRA (0.53) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL20032552 | 0.86 | PDGFRA (0.51) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL20032550 | 0.86 | KDR (0.52) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL31554535 | 0.86 | FLT3 (0.54) | PDGFRAKDRFGFR2METAXL | |
| SCHEMBL22960033 | 0.85 | KDR (0.50) | PDGFRAKDRFGFR2METAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-17 | — | — | US | disclosed |
| US-10676462-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | PDGFRA 155/4885KDR 27/4885FGFR2 365/4885 |
| US-10676462-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | PDGFRA 155/4885KDR 27/4885FGFR2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.